| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYPB |
| Uniprot No | P23284 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 34-216aa |
| 氨基酸序列 | MKHHHHHHASDEKKKGPKVTVKVYFDLRIGDEDVGRVIFGLFGKTVPKTV DNFVALATGEKGFGYKNSKFHRVIKDFMIQGGDFTRGDGTGGKSIYGERF PDENFKLKHYGPGWVSMANAGKDTNGSQFFITTVKTAWLDGKHVVFGKVL EGMEVVRKVESTKTDSRDKPLKDVIIADCGKIEVEKPFAIAKE |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CYPB(Cyclophilin B)重组蛋白的参考文献概览：
---
1. **"Recombinant human cyclophilin B regulates HIV-1 replication through interaction with viral capsid protein"**
*Authors: Li H, et al.*
摘要：研究利用重组人CYPB蛋白，揭示其通过与HIV-1衣壳蛋白结合调控病毒复制的作用机制，为抗病毒治疗提供新靶点。
2. **"Crystal structure of recombinant cyclophilin B complexed with cyclosporin A"**
*Authors: Gothel SF, et al.*
摘要：通过重组表达CYPB蛋白并解析其与免疫抑制剂环孢素A的复合物晶体结构，阐明了CYPB的底物结合位点及构象变化。
3. **"Recombinant cyclophilin B promotes collagen secretion in osteogenesis imperfecta fibroblasts"**
*Authors: Smith T, et al.*
摘要：发现重组CYPB蛋白可纠正成骨不全症患者胶原分泌缺陷，表明其在胶原折叠中的关键辅助功能及潜在治疗价值。
---
注：以上文献为示例，实际引用时需核对具体来源及发表年份。如需精准文献，建议通过PubMed或Google Scholar以关键词检索。
**Background of Recombinant CYPB Protein**
Cyclophilin B (CYPB), a member of the immunophilin family, is a 21 kDa protein with peptidyl-prolyl isomerase (PPIase) activity, facilitating the cis-trans isomerization of proline residues during protein folding. It localizes primarily in the endoplasmic reticulum (ER) and functions as a chaperone, aiding in the maturation of secreted or membrane-bound proteins. CYPB also interacts with the ER-resident protein complex, including calreticulin and calnexin, to ensure proper glycoprotein folding.
Recombinant CYPB is produced via genetic engineering, typically expressed in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cell lines), enabling large-scale purification for research and therapeutic applications. Its recombinant form retains enzymatic activity and structural integrity, making it a valuable tool for studying protein folding mechanisms, immune regulation, and viral replication. Notably, CYPB interacts with cyclosporine A (CsA), forming complexes that inhibit calcineurin, a key pathway in T-cell activation.
CYPB is implicated in various diseases. It serves as a cofactor for hepatitis C virus (HCV) replication, contributing to viral assembly. Dysregulated CYPB expression is linked to autoimmune disorders (e.g., rheumatoid arthritis) and cancers, where it may promote tumor progression via ER stress modulation or immune evasion. Additionally, CYPB’s role in collagen biosynthesis highlights its relevance in connective tissue disorders.
The development of recombinant CYPB has advanced drug discovery, particularly for antiviral and immunosuppressive therapies. Its structural and functional versatility continues to drive research into novel therapeutic targets and molecular pathways.
×
